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W ith the increasing number of older adults worldwide,  the average age of patients with 
hematopoietic malignancies is expected to increase 
every year.  One of the diseases for which old age is a 
particularly poor prognostic factor is lymphoma [1].  In 
addition,  there is an increase in the risk of treat-
ment-related mortality in elderly patients.  Finally,  old 
age increases the likelihood of various disease factors 
and patient factors,  including a history of other diseases 
and organ disorders,  resulting in a poor response to 
chemotherapy.
To date,  no treatment has been found to be superior 
to cyclophosphamide,  doxorubicin,  vincristine,  and 
prednisone (CHOP) therapy as an initial therapy in 
both peripheral T-cell lymphoma not otherwise speci-
fied (PTCL-NOS) and angioimmunoblastic T-cell lym-
phoma (AITL).  The International T-cell Lymphoma 
Project [2],  a retrospective analysis of a prospective 
clinical trial [3],  and a small-scale prospective clinical 
trial [4] reported an overall survival (OS) rate of 
30-45% and a progression-free survival (PFS) rate of 
20-30% among patients who received CHOP therapy.  
According to a Swedish data registry [5],  in CHOP or 
cyclophosphamide,  doxorubicin,  vincristine,  etopo-
side,  and prednisone (CHOEP) therapy,  the OS and 
PFS rates were respectively 28.1% and 21.3% in PTCL-
NOS and 31.6% and 20.4% in AITL.  Although the 
international prognostic index is low in these cases,  
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Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL).  
However,  the timing of romidepsin administration remains controversial.  Romidepsin was launched in Japan 
as a consolidation therapy agent after conventional salvage chemotherapy with gemcitabine,  dexamethasone,  
and cisplatin (GDP).  GDP therapy will be administered every 3 weeks.  If complete response,  partial response,  
or stable disease is confirmed after 2-4 GDP cycles,  romidepsin will be administered every 4 weeks.  The pri-
mary endpoint is a 2-year progression-free survival rate.  Patients participating in this study and undergoing 
treatment can expect results similar to or better than those of conventional therapies.
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indicating good prognosis,  the survival rate remain 
poor.  A retrospective analysis of a prospective clinical 
trial in Germany found that PTCL patients with normal 
levels of lactate dehydrogenase showed improved PFS 
rates using CHOEP therapy [3] as did PTCL patients 
under the age of 60 years in the Swedish data registry 
[4].  However,  neither study showed a difference in OS 
rates between CHOP and CHOEP therapies.  A previ-
ous clinical trial in which PTCL patients were adminis-
tered 4-6 courses of CHOEP therapy as an initial ther-
apy for CHOP [6] and a review of various studies and 
trials using this same protocol [7].  However,  the effi-
cacy of CHOEP therapy has not yet been investigated in 
transplant-ineligible patients aged 65 years and older.  
In young people,  upfront autologous or allogeneic 
transplantation was generally recommended,  but mul-
tiple trials have found no difference in long-term sur-
vival following the use of CHOEP or CHOP therapy 
alone [4].  A multicenter study in Japan found that 
dose-adjusted etoposide,  prednisone,  vincristine,  
cyclophosphamide,  and doxorubicin (DA-EPOCH) 
therapy was effective [8],  although this has not yet been 
confirmed.
There are no standard treatments in elderly trans-
plant-ineligible relapsed/refractory PTCL patients.  
There have been reports on the effectiveness of gemcit-
abine,  dexamethasone,  and cisplatin (GDP) therapy in 
relapsed/refractory PTCL patients,  although it has been 
used in only a small number of cases [9 , 10].  The 
60-70% response rate to GDP therapy is promising,  but 
the median disease-free survival rate is still unsatisfac-
tory at 9-10 months.  To date,  no treatment methods 
with the potential to prolong OS have been developed,  
and studies focusing on the prolongation of OS as the 
primary endpoint are difficult to conduct.
Phase I / II trials on romidepsin have been con-
ducted in Japan [11].  These trials found that romidep-
sin caused few critical side effects other than temporary 
reduced blood cell count,  and despite its being a sin-
gle-agent therapy,  the overall response rate was 25% 
(15% complete remission) [11].  Clinical trials on the 
prevention of relapse following autologous transplants 
are in progress in the United States,  and no large-scale 
adverse events have been reported thus far.  However,  
there are no clinical trials on consolidation therapies 
following salvage chemotherapy in elderly trans-
plant-ineligible patients with relapsed/refractory PTCL.  
In Japan,  only single-agent administration is covered by 
insurance and is deemed safe.  Although a standard 
treatment has not been established in PTCL,  future 
developments in treatment can be facilitated by intro-
ducing romidepsin,  which was launched in Japan as a 
consolidation therapy agent following conventional 
salvage chemotherapy and from which only short-term 
effects can be expected.
Endpoints
The primary endpoint is a 2-year PFS rate.  The PFS 
rate is measured from the start date,  which is the day of 
registration,  until either the day on which the patient’s 
condition is deemed to have progressed/relapsed or the 
date of death from any cause,  whichever comes first.  
Patients without progression are censored on the final 
day on which the patient’s condition is confirmed not to 
have progressed.
The secondary endpoints are as follows: complete 
response (CR) in GDP + romidepsin therapy rate; re-
sponse [CR + partial response (PR)] rate; adverse 
events; OS; time to response (defined as the period 
from the registration day until the day on which a 
response (PR and higher) is first confirmed); the best 
response to GDP therapy; the best response to romide-
psin therapy; the best response to treatment according 
to disease risks (e.g.,  international prognostic index,  
prognostic index for T-cell lymphoma); quality of life 
(QOL); inpatient-outpatient period; necessary expenses;  
and pathology-centered diagnosis.
Safety will be evaluated on the basis of the National 
Cancer Institute Common Terminology Criteria for 
Adverse Events ver.  4.0.  The SF-36®,  a comprehensive 
survey to measure patient health,  and the Quality of 
Life Questionnaire for Cancer Patients Treated with 
Anticancer Drugs (QOL-ACD),  a QOL measurement 
tool specifically for cancer patients,  will be used to sur-
vey QOL.  The inpatient-outpatient period will be sur-
veyed during the inpatient and outpatient treatment 
periods after the completion of treatment.  To deter-
mine the necessary expenses,  the total estimated 
charges on all the patients’ bills delivering the treatment 
from the start of therapy until the final response evalu-
ation will be added.  
Eligibility Criteria
Patients who meet all the inclusion criteria and do 
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not fall under any of the exclusion criteria can register in 
this study.  The inclusion and exclusion criteria are pro-
vided in Table 1.
Methods
Study design. This study is a phase II multicenter 
open-label,  single-arm trial.  We will examine the effi-
cacy and safety of GDP therapy and romidepsin therapy 
as salvage chemotherapies for elderly transplant-ineligi-
ble patients with relapsed/refractory PTCL.  Currently,  
there is no standard treatment for relapsed/refractory 
PTCL in elderly transplant-ineligible patients; there-
fore,  we will perform this study as a nonrandomized 
confirmatory trial to determine whether the aforemen-
tioned therapies should be standardized.  This study has 
been registered in the Japan Registry of Clinical Trials 
(jRCT,  registration number: jRCTs031180445).
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Table 1　 Eligibility­criteria
Inclusion­criteria
 1) The­patient­is­aged­65 years­or­older­at­the­time­of­registration.
 2) The­patient­received­a­diagnosis­of­peripheral­T-cell­lymphoma­(PTCL-NOS­or­AITL­according­to­the­2016­WHO­classiﬁcation), ­previ-
ously­underwent­more­than­one­treatment­regimen, ­is­not­eligible­for­autologous­or­allogeneic­stem-cell­transplantation, ­and­presents­
with­relapsed/refractory­disease.
 3) The­patient­has­a­lesion­that­is­measurable.
 4) The­patientʼs­Eastern­Cooperative­Oncology­Group­Performance­Status­at­the­time­of­registration­is­0-2. ­ ­
This­status­can­be­achieved­after­a­previous­prednisone­dose­(approximately­1 week­of­prednisone­administration­is­permissible).
 5) The­patientʼs­major­organ­functions­have­been­maintained­and­the­patient­satisﬁes­the­following­criteria:
5-a)­­The­patient­has­a­neutrophil­count­of­at­least­1,000/μl.
5-b)­­The­patient­has­a­platelet­count­of­at­least­50,000/μl.
5-c)­­The­patientʼs­cardiac­function­has­an­ejection­fraction­of­over­50%­(echocardiogram­or­myocardial­scintigraphy).
5-d)­­The­patientʼs­arterial­blood­gas­analysis­shows­a­PaO2­of­over­60 mmHg­or­the­percutaneous­oxygen­saturation­measurement­shows­
an­SpO2­of­over­93%­(room­air).
5-e)­­The­patientʼs­serum­aspartate­aminotransferase­or­alanine­aminotransferase­ is­ less­ than­ﬁve­times­the­maximum­value­of­ the­
facility­standard. ­
5-f)­­The­patientʼs­creatinine­clearance­is­over­30 ml/min­(Cockcroft‒Gault).
 6) The­patient­has­received­a­notiﬁcation­and­the­trial­has­been­adequately­explained­to­the­patient­by­the­facility­investigator­(assigned)­
using­the­designated­consent­form­and­explanatory­materials. ­The­patient­has­provided­written­informed­consent­for­voluntary­partici-
pation­in­the­trial.
Exclusion­criteria
 1) The­ patient­ has­ been­ clinically­ diagnosed­ with­ testis­ or­ central­ nervous­ system­ (brain, ­ spinal­ cord, ­ medullary­ cavity)­ invasion.
(Examination­of­the­cerebrospinal­ﬂuid­or­an­MRI­of­the­brain­is­not­mandatory.)
 2) The­patient­has­severe­hepatic, ­renal, ­cardiac, ­or­pulmonary­dysfunction, ­diabetes, ­or­hypertension.
 3) The­patient­has­interstitial­pneumonia­or­pulmonary­ﬁbrosis. ­(If­either­is­determined­by­a­plain­X-ray­image­of­the­chest, ­the­patient­
shall­not­be­able­to­register. ­Mild­cases­indicated­for­the­ﬁrst­time­on­a­chest­CT­scan­shall­not­be­excluded. ­Patients­whose­lungs­
have­been­previously­exposed­to­radiation­shall­be­excluded, ­as­they­are­at­a­high­risk­of­developing­interstitial­pneumonia.)
 4) The­patient­presents­with­a­QTc­interval­that­measures­over­500 ms­on­an­electrocardiogram.
 5) The­patient­has­tubercular­disease, ­herpetic­simplex­keratitis, ­systemic­mycoses, ­or­any­other­active­infection.
 6) The­patient­has­had­acute­myocardial­infarction, ­deep­vein­thrombosis, ­or­pulmonary­embolism­within­the­past­6 months.
 7) The­patient­has­an­active­and­advanced-stage­double­cancer­(synchronous­double­cancer­and­metachronous­double­cancer­with­a­
disease-free­interval­of­less­than­5 years. ­However, ­lesions­that­correspond­to­carcinoma­in situ­of­the­uterine­cervix, ­stomach, ­or­
colon­deemed­to­have­been­cured­by­local­treatment­are­not­considered­active­double­cancers).
 8) The­patient­is­HBs­antigen-positive, ­HCV­antigen-positive, ­HTLV-1­antigen-positive, ­or­HIV­antibody-positive. ­(HBs­antibody-­and­
HBc­antibody-positive­patients­shall­not­be­excluded. ­If­HBV-DNA­is­detected, ­the­patient­shall­be­excluded. ­An­HIV­antibody­test­is­
not­mandatory).
 9) The­patient­has­a­history­of­severe­drug­hypersensitivity.
10) The­patient­lacks­the­ability­to­provide­consent­or­is­suﬀering­from­symptoms­such­as­those­of­dementia.
11) The­patient­has­undergone­local­radiotherapy­less­than­2 weeks­prior­to­the­trial.
12) The­representative­doctor­of­the­facility­or­investigator­deems­the­patient­unﬁt­to­participate­in­the­trial.
Intervention. The protocol will commence within 
4 weeks after patient registration.  The attending physi-
cian will decide whether the patient should undergo 
inpatient or outpatient treatment.  Figure 1 outlines this 
trial treatment.  GDP therapy will be administered 
every 3 weeks.  A 1,000 mg/m2/day dosage of gemcit-
abine will be administered intravenously on days 1 and 
8,  a 40 mg/day dosage of dexamethasone will be 
administered orally or intravenously on days 1-4,  and a 
75 mg/m2/day dosage of cisplatin will be administered 
intravenously on day 1.  After two courses of GDP ther-
apy,  an interim response evaluation will be carried out 
via positron emission tomography-computed tomogra-
phy (PET-CT) or CT scan.  The evaluation criteria in the 
Revised Response Criteria for Malignant Lymphoma 
[11] will be used to evaluate the tumor shrinkage 
response.  In cases of CR,  PR,  or stable disease (SD),  
two additional courses of GDP therapy will be added.  
However,  if the doctor in charge determines that the 
patient does not have the required tolerability for rea-
sons unrelated to his or her disease status,  no addi-
tional GDP therapy will be added,  or they may choose 
to add just one additional course.  Patients who are 
unable to achieve a result better than SD before the 
interim response evaluation after the two courses of 
GDP therapy [progressive disease (PD)] and those who 
are confirmed as having a PD during the treatment pro-
tocol shall stop the treatment protocol at that point.  
Patients who complete the planned GDP therapy will 
undergo a GDP therapy final response evaluation via CT 
and PET-CT scan after the conclusion of the final 
course.
Those who are deemed to have achieved CR,  PR,  or 
SD based on the response evaluation after the final GDP 
therapy will undergo romidepsin therapy every 4 weeks.  
One course comprises romidepsin 14 mg/m2/day 
administered intravenously once per day on days 1,  8,  
and 15.  A final response evaluation will be carried out 
6 months after the end of the treatment,  which is to 
continue for 12 courses over the course of one year.
Standard for dose adjustment.
Gemcitabine
1)  In cases where Grade 3 nonhematological toxicity 
(excluding nausea,  vomiting,  and hair loss) 
appears,  the dose will be decreased by 25% in the 
next course.
2)  In cases where nonhematological toxicity or renal 
dysfunction of Grade 4 (serum Cr > 2.26 mg/dl) 
appears,  administration will be discontinued 
immediately and the patient will be withdrawn 
from the study.
3)  In cases where the patient is 80 years old or above,  
the initial dose will be decreased by 75% in the 
next course.
Dexamethasone
If any of the following adverse events are observed,  
administration will be discontinued.
1)  If gastric/duodenal ulcer is confirmed by endos-
copy despite the prophylactic administration of a 
proton pump inhibitor or histamine H2 receptor 
antagonist (Grade 2 or higher).
2)  If hyperglycemia requiring insulin treatment 
occurs (hyperglycemia Grade 3: fasting blood 
glucose ≥ 250 mg/dl) or if blood glucose control 
is poor even after insulin is used.
3)  If administration of a major tranquilizer or anti-
depressant/antimanic drug is required after the 
initiation of R-GDP therapy.
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Eligibility veriﬁed/cases registered
GDP (2 courses)
CR/PR/SD PD
Protocol
terminated
Protocol
terminated
GDP (2 courses)＊
GDP therapy ﬁnal response evaluation
CR/PR/SD PD
Romidepsin therapy (12 courses)
Final response evaluation (2 years after the 
commencement of treatment)
Follow-up/observation
GDP therapy interim response evaluation
Fig. 1　 Treatment­outline­ ­
＊­The­addition­of­0­-2­courses­of­GDP­therapy­will­be­determined­by­
the­doctor­in­charge­according­to­the­patientʼs­tolerability.
Cisplatin
1)  The dose will be reduced depending on renal 
function at the beginning of each course (includ-
ing the initial starting dose).   
Serum Cr 1.58-2.25 mg/dl: 25% decrease from 
the next course.   
Serum Cr > 2.26 mg/dl: administration will be 
discontinued from the next course,  and the 
patient will be taken off the study.
2)  Nonhematological toxicity  
In cases where Grade 3 nonhematological toxic-
ity (except nausea,  vomiting,  and depilation) 
appears,  the dose will be decreased by 25% from 
the next course.   
In cases where Grade 4 nonhematological toxic-
ity appears,  administration will be discontinued 
from the next course,  and the patient will be 
withdrawn from the study.
3)  In cases where the patient is 80 years old or above,  
the initial dose will be decreased by 75%.
Romidepsin
In patients with platelet count < 50,000 /μl,  neutro-
phil count <1,000 /μl,  Grade 3 nonhematological toxic-
ity,  QTc interval >500 ms,  or arrhythmia,  administra-
tion will be discontinued.
Safety evaluation following the conclusion of treat-
ment
Post-therapy follow-up and observation will include 
a medical examination and blood test once every 
3 months,  and diagnostic imaging (CT scan) and eval-
uation of the intercurrent lesions at the time of registra-
tion once every 6 months.  During follow-up,  the pres-
ence or absence as well as the levels of adverse events 
will be evaluated and recorded on the patient’s medical 
chart.
Efficacy evaluation following the conclusion of treat-
ment
Efficacy evaluation following the end of the treat-
ment will consist of a medical examination and blood 
test once every 3 months,  and diagnostic imaging (CT) 
and evaluation of the intercurrent lesions at the time of 
registration once every 6 months.  The absence or pres-
ence of a relapse,  deterioration,  or secondary cancer 
will be clinically assessed during all other times.
Statistical Considerations
Sample size. In a South Korean report on patients 
treated with GDP therapy,  the median PFS was 
9.3 months and the 2-year PFS rate was 20% [8],  while 
in a Chinese report utilizing GDP the median PFS was 
5.4 months [10].  Using these data as a reference,  the 
2-year PFS rate threshold will be set at 20%.  In a 
Japanese study on romidepsin [11],  the PFS rate was 
20% at 17 months,  and the median PFS was 5.6 months.  
In an overseas study on romidepsin [12],  the 2-year 
PFS rate was 20% and the median PFS survival was 4 
months.  Based on these data,  20% will be added to 
GDP and the expected value will be set at 40%.  When 
the number of patients necessary was calculated via a 
simulation based on survival analysis under the condi-
tions of α = 0.10 (one sided),  β = 0.20,  registration 
period of 3 years,  and observation period of 2 years,  
the number of patients was calculated as 27.  Considering 
patients who may be ineligible after registration,  the 
sample size was set at 30.
Interim analyses and monitoring. No interim 
analyses will be carried out.  Routine monitoring will be 
conducted once a year.  Centralized monitoring will be 
conducted based on the data on case reports collected 
via Electronic Data Capture.
Statistical methods. The full analysis set (FAS) 
will include all registered patients.  Regarding the pro-
tocol rules for treatment and combination therapy,  the 
per-protocol set will exclude patients from the FAS who 
do not meet the eligibility criteria or who meet the 
exclusion criteria,  as well as those who have taken pro-
hibited concomitant medication or prohibited combi-
nation therapy.  In addition,  patients for whom serious 
violations of the protocol are noted (approval not 
obtained,  serious violations concerning trial proce-
dures) will be excluded.  From the registered patients,  
the group excluding those who do not undergo any 
treatment will be identified as the safety analysis set.
Regarding efficacy evaluation,  FAS is the main anal-
ysis set.  To measure the response rate,  the point estimate 
and an 80% confidence interval will be calculated.  The 
PFS,  OS,  and time to response will be estimated using 
the Kaplan-Meier method.  The 80% confidence interval 
for survival function will be calculated using Greenwood’s 
formula.  All the safety analyses will be performed rela-
tive to the safety evaluation set.  For adverse events and 
serious adverse events,  the point estimate of the pro-
portion of occurrence and a 95% confidence interval 
will be calculated.  Regarding the SF-36® and QOL-ACD,  
any temporal changes will be summarized.
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Discussion
Results similar to or better than those of conven-
tional therapies are anticipated in patients participating 
and receiving treatment in this study.  The median PFS 
after GDP therapy in patients with PTCL has been 
reported to range from 9 to 10 months.  Currently,  no 
therapy is available to prolong the OS in patients with 
PTCL [9 , 10].  Many patient factors affect OS in elderly 
patients,  and their conditions are often complicated by 
previous illnesses and organ damage.  Therefore,  when 
the treatment intensity in elderly patients is increased to 
a level similar to that in a young person,  it often 
becomes difficult to counter a tumor’s resistance to 
therapy.  Romidepsin has the potential to be effective 
against tumors other than hematopoietic malignancies.  
Hence,  we can expect romidepsin to influence treat-
ment development and to provide useful data for other 
cancerous tumors such as acute lymphocytic leukemia 
[13].  Two studies have described that the median time 
for response to romidepsin was 11.1 months [11 , 12];  
thus,  we hypothesize that 12 months of treatment may 
be acceptable in elderly patients.  It is important to 
comprehensively conduct medical evaluations by con-
sidering the clinical,  QOL,  and financial aspects.  To 
date,  we have been able to obtain information only on 
the impacts of therapy choices on patients’ QOL and 
financial circumstances,  the latter of which is difficult to 
verify.  However,  from the results of this clinical study,  
we can also expect to obtain information on the estab-
lishment of better therapies in patients with PTCL in the 
future.
Ethics approval and consent to participate. This 
study was approved in January 2019 by the clinical 
research central ethics review committee of a national 
hospital organization.
Prior to the commencement of this study,  the prin-
cipal investigator or investigators will obtain written 
informed consent based on each patient’s free will.  
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